FY2026 Earnings Estimate for Exagen Issued By William Blair

Exagen Inc. (NASDAQ:XGN) – Stock analysts at William Blair issued their FY2026 EPS estimates for Exagen in a research note issued to investors on Wednesday, March 12th. William Blair analyst A. Brackmann forecasts that the company will earn ($0.23) per share for the year. William Blair has a “Outperform” rating on the stock. The consensus estimate for Exagen’s current full-year earnings is ($0.88) per share.

Other equities analysts have also issued research reports about the stock. Cantor Fitzgerald restated an “overweight” rating and set a $8.00 price target on shares of Exagen in a research report on Monday, January 13th. Canaccord Genuity Group upped their price objective on shares of Exagen from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Friday, January 3rd.

Exagen Trading Up 6.3 %

XGN opened at $3.56 on Thursday. The company has a debt-to-equity ratio of 1.54, a current ratio of 4.05 and a quick ratio of 4.05. Exagen has a 12-month low of $1.30 and a 12-month high of $6.22. The firm’s fifty day moving average price is $3.78 and its 200 day moving average price is $3.57. The stock has a market capitalization of $62.79 million, a PE ratio of -3.79 and a beta of 1.40.

Hedge Funds Weigh In On Exagen

A number of hedge funds have recently added to or reduced their stakes in the company. Toronto Dominion Bank acquired a new position in Exagen in the fourth quarter worth approximately $3,655,000. Driehaus Capital Management LLC bought a new stake in shares of Exagen in the fourth quarter valued at approximately $1,716,000. Northern Trust Corp lifted its position in Exagen by 16.7% in the fourth quarter. Northern Trust Corp now owns 18,375 shares of the company’s stock worth $75,000 after purchasing an additional 2,630 shares during the period. Marshall Wace LLP bought a new position in Exagen in the fourth quarter worth $66,000. Finally, Kennedy Capital Management LLC lifted its position in Exagen by 8.8% in the fourth quarter. Kennedy Capital Management LLC now owns 184,473 shares of the company’s stock worth $756,000 after purchasing an additional 14,920 shares during the period. Institutional investors and hedge funds own 75.25% of the company’s stock.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).